'김갑성' 기자의 전체기사
-
메나리니 그룹, 제67회 미국혈액학회 연례 학술대회에서 ELZONRIS®(tagraxofusp…
모구 형질세포양 수지상세포 종양(BPDCN) 환자들에게 중요한 발견을 담은 2건의 구두 발표를 포함하여 총 5개의 초록에 걸친 데이터 공개 BPDCN은 피부, 골수, 혈액에 주로 영향을 미치는 매우 공격적인 희귀 혈액암 이탈리아 피렌체 및 뉴욕, 2025년 11월 25일 -- 세계적인 제약·진단 기업인 메나리니 그룹(Menarini Group)과 메나리니 그룹의 전액 출자 자회사이자 암 환자들에게 혁신적인 종양 치료제를 제공하는 데 주력하는 스템라인 테라퓨틱스(Stemline Therapeutics)가 오늘 12월 6일부터 9일까지 올랜도에서 열리는 미국혈액학회(American Society of Hematology, ASH) 연례 학술대회에서 ELZONRIS® (tagraxofusp-erzs) 관련 신규 데이터를 발표한다고 밝혔다. 발표 중에는 tagraxofusp, azacitidine, venetoclax 3제 요법 결과를 다루는 구두 세션이 포함된다. 이 요법은 높은 반응률과 이식 전 단계(bride to transplant) 도달률, 그리고 내약성을 함께 보여 모구 형질세
- 김갑성 기자
- 2025-11-25 17:44
-
Mazdutide 9mg Supplementary Application Accepted for Rev…
SAN FRANCISCO and SUZHOU, China, Nov. 25, 2025 -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, and ophthalmologic diseases, announces that the supplementary application for the 9 mg dosage of mazdutide, an innovative glucagon (GCG)/ glucagon-like peptide-1 (GLP-1) dual receptor agonist, for the long-term weight management in adults with moderate to severe obesity has been accepted for review by
- 김갑성 기자
- 2025-11-25 17:00
-
FROM MEDICAL SUPPLIER TO MULTI-INDUSTRY LEADER: LIVINGSTONE IN…
SYDNEY, Nov. 25, 2025 -- One of Australia's largest medical supply companies is celebrating its unique warehousing and supply chain strategy that has seen it grow into a leading manufacturer, importer, and supplier to more than 20 key industries. Livingstone International supplies more than 65,000 essential health, hygiene, education, beauty, and hospitality products to industries including aged care, schools and universities, hair and skin clinics, pharmacy, dental, mining, and government. Livingstone International Managing Director, Daniel Linn, said the company has no
- 김갑성 기자
- 2025-11-25 05:00
-
HKeyBio Launches the HKEY-AIDMD 3.0--a Next-Generation Pla…
[ 메디채널 김갑성 기자 ] The newly upgraded HKEY-AIDMD 3.0 model library features nearly 300 autoimmune and allergy-related disease models. For multiple major indications, HKeyBio has established four-dimensional (4D) model pools that simulate clinical heterogeneity, providing a mechanism-driven model selection platform for evaluating multi-target combination therapies. The HKEY-AIDMD 3.0 omics database integrates spatiotemporal single-cell and spatial omics across various tissues and immune systems from the model library. This significantly improves resolution in identifying the differentiating ad
- 김갑성 기자
- 2025-11-25 00:30
-
Menarini Group Announces New Data on ELZONRIS® (tagraxo…
Data spans five abstracts including two oral presentations with important findings for patients living with blastic plasmacytoid dendritic cell neoplasm (BPDCN) BPDCN is a highly aggressive, orphan hematologic malignancy that primarily affects skin, bone marrow, and blood FLORENCE, Italy and NEW YORK, Nov. 24, 2025 -- The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group, focused on bringing transformational oncology
- 김갑성 기자
- 2025-11-24 23:34
-
Alzheimer's Association Statement on Oral Semaglutide Phas…
- Results Underscore Need for Continued Research and Diverse Treatment Pipeline CHICAGO, Nov. 24, 2025 -- The Alzheimer's Association is disappointed that the evoke and evoke+ clinical trials did not demonstrate a statistically significant reduction in Alzheimer's disease progression. The studies tested an oral semaglutide pill for the treatment of early-stage symptomatic Alzheimer's disease. "While these results are not what we had hoped for, they will contribute to our understanding of this devastating and fatal disease," said Joanne Pike, DrPH, Alzheimer's A
- 김갑성 기자
- 2025-11-24 23:19
-
ToolGen and GenEditBio Enter Strategic Cross-License Agre…
Integrates ToolGen's best-in-class CRISPR-Cas9 platform with GenEditBio's industry-leading lipid nanoparticle (LNP) delivery technology Pursues a "once-and-done" treatment paradigm for diseases with high unmet medical needs SEOUL, South Korea, Nov. 24, 2025 -- ToolGen Inc. (KOSDAQ: 199800), a leading genome editing company based in Korea, announced today that it has entered into a strategic cross-license agreement with GenEditBio Limited ("GenEditBio"), a Hong Kong-headquartered clinical-stage biotechnology company specializing in novel deliveries, in
- 김갑성 기자
- 2025-11-24 22:00
-
Kelun-Biotech Announces Phase III Trial of Sac-TMT in Com…
CHENGDU, China, Nov. 24, 2025 -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced today that the Independent Data Monitoring Committee (IDMC) concluded that the Phase III clinical study (OptiTROP-Lung05) of the company's TROP2 ADC sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870), in combination with MSD's anti-PD-1 therapy KEYTRUDA®[1] (pembrolizumab), as a first-line treatment for PD-L1-positive advanced non-small cell lung cancer (NSCLC), has demonstrated a statistically significant and clinically meaningful improvemen
- 김갑성 기자
- 2025-11-24 20:00
-
Triple the Probiotics, Triple the Relief: Life-Space Launche…
Engineered by Australia's leading probiotics expert, this high CFU probiotic delivers the ultimate gut defense, helping to reduce gut transit time by up to 18 hours. SINGAPORE, Nov. 24, 2025 -- Life-Space, Australia's No.1 probiotic brand, proudly unveils Triple Strength Probiotics, a flash charged probiotic designed to deliver intensive gut health support for those with more demanding digestive needs. With 15 premium strains and three times the beneficial bacteria of regular Broad Spectrum Probiotic formulations, this high-strength solution delivering 96 billion CFU's per capsule repr
- 김갑성 기자
- 2025-11-24 18:29
-
HoneyNaps Accelerates Clinical Trial Pipelines with FDA-Clea…
[ 메디채널 김갑성 기자 ] Enhancing Clinical Efficiency with AI Sleep Analysis: Cutting Both Cost and Time Joint Clinical Studies with CROs: SOMNUM™ AI Sleep Scoring Drives Higher Efficiency FDA-cleared AI solution shortens clinical trial timelines while ensuring data reliability Expanded global partnerships with CROs enable a large-scale clinical data analysis platform BOSTON, Nov. 24, 2025 -- HoneyNaps, an AI-driven sleep-medicine technology company, announced that its AI-based sleep disorder diagnostic support software, SOMNUM™, which recently received clearance from the U.S. Food a
- 김갑성 기자
- 2025-11-24 17:24
- 1포리프 굿마팻 (누바디 굿바이 마이팻) 다이어트 건강기능식품 출시
- 22021년 식품분석전문가 1급/2급 검정자격시험 안내
- 3투썸플레이스, 초콜릿 애프리콧 무스 출시
- 4아임웹, CRM 기능 출시… 고객 행동 데이터 기반 마케팅 지원
- 5하만카돈, AURA STUDIO 4 블루투스 스피커 출시
- 6대구오페라하우스 - 20주년 기념 골든 보이스 시리즈Ⅲ, 테너 콘서트
- 7만성질환자들의 유료독감백신접종에 정책적인 배려가 필요하다
- 82021년 대학생기자단 모집
- 9대한약물영양의학회 2020년 추계학술대회
- 10대한영양제처방학회 춘계학술대회 성황리에 마쳐
2026-01-31_SAT
- JOHNNIE WALKER TOASTS MUSIC'S BIGGEST WEEKEND WITH THE GO GO HIGHBALL 20:58
- Sanyou Bio's Decade: From an Intelligent Super-Trillion Antibody Library to the "Innovation Hub for Original Drug Discovery" 16:15
- CANADA BACKS NEW DEFENCE, SECURITY AND RESILIENCE BANK 12:05
- Origin Agritech Announces Fiscal Year 2025 Results 06:00
- White Pearl Acquisition Corp. Announces Pricing of $100 Million Initial Public Offering 05:47
- Planet Green Holdings Corp. Provides Response to Unusual Market Action 05:05
- SKF completes previously announced divestment of non-core aerospace operation in Elgin, USA 03:36
발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.
UPDATE: 2026년 01월 31일 22시 40분